Latest Chinese Drug Coverage Comes With Steep Price Cuts, Caveats
But Bigger Volumes Await
Executive Summary
November negotiations in China over the prices of 67 new drugs have resulted in record price cuts, averaging around 62% overall and 65% for anti-tumor products. But the sting is alleviated by the prospect of substantial volume increases.
You may also be interested in...
Pharma Execs Urge 'Balance' In China Payer Price Negotiations
The annual reimbursement price negotiations between pharma firms and China’s National Healthcare Security Administration are just around the corner. While some have chosen to walk away from the process completely, others including majors BeiGene and Hengrui are girding up for another round of potentially deep cuts.
Balancing Act: Orphan Drug Makers Slash Prices In China As New Mechanism Allures
From Biogen to Takeda, multinationals have been cutting prices in China in a bid to seize the emerging market for rare disease treatments, as Beijing strives to expand market access.
Rare Chance Or Passing Opportunity: China Expands Orphan Drug Coverage With Steep Price Cuts
Latest national medical insurance negotiations results show orphan drugs are covered, but Biogen’s Spinraza gets a 95% price cut. Getting coverage, rather holding out for a high price, really makes more sense in the emerging Chinese market for rare disease drugs, industry observers say.